Status:
UNKNOWN
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Lead Sponsor:
Leiden University Medical Center
Conditions:
Neurofibromatosis 2
Eligibility:
All Genders
18+ years
Brief Summary
Bevacizumab can be an effective treatment for individuals with NF2 and improve different nerve functions (like hearing, tinnitus or balance problems) and the quality of life of NF2 patients. However, ...
Eligibility Criteria
Inclusion Criteria:
- Patients aged 18 years or older
- Confirmed diagnosis of NF2 by revised Manchester criteria
- Provided written informed consent
- Patients must have measurable disease, defined as at least one VS > 0.4 ml (on volumetric analysis) that can be accurately measured by contrast-enhanced T1-weighted cranial MRI scan.
- Eligible and planned for bevacizumab treatment
Exclusion Criteria:
- Patients with a contra-indication for PET and MRI, such as pregnancy and metal elements.
- Patients with a known allergy to substances used in this study
- Concurrent treatment with Everolimus
Key Trial Info
Start Date :
October 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05685836
Start Date
October 20 2022
End Date
December 31 2024
Last Update
March 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leiden University Medical Center
Leiden, South Holland, Netherlands, 2333ZA